Eli Lilly and

2 days ago · reuters.com

The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that ​has spread to other parts of the body, the drugmaker ‌said on Friday.

2 days ago · prnewswire.com

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor  In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone, among patients with ESR1-mutated MBC The all-oral combination of Inluriyo and Verzenio gives patients a treatment approach that targets the two central drivers of ER+ breast cancer, with an established tolerability profile and no new monitoring required  INDIANAPOLIS, Sept. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

4 days ago · fool.com

Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions.

5 days ago · zacks.com

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

5 days ago · fool.com

Eli Lilly's breakthroughs in its core therapeutic area are driving excellent financial results. The company could hit significant headwinds if it encounters clinical setbacks and ceases to innovate.

6 days ago · benzinga.com

Shares of Eli Lilly and Company (NYSE:LLY) are trading higher Tuesday morning following positive previews of its late-stage obesity and diabetes pipeline.

6 days ago · 247wallst.com

Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how the story reads.

6 days ago · 247wallst.com

Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.

6 days ago · zacks.com

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.99% move from its prior day's close.